Contract development and manufacturing organization (CDMO) Alcami has reached an agreement to be acquired by Madison Dearborn Partners (MDP), a private equity firm based in Chicago. MDP will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation. The CDMO’s management team, led by chief executice officer, president, and chairman, Stephan Kutzer, will continue to lead the company. The transaction is expected to be completed in the third quarter of 2018.

“The entire Alcami team is excited to further enhance and evolve the small to mid-size pharma growth engine. As we enter our next stage of progress as a leading global, clinically-focused and fully-integrated contract development and manufacturing organization (CDMO), we are proud to partner with MDP to expand our talented employee base and further develop our capabilities. There’s no doubt we will continue to serve our clients with dedication, innovative solutions, and our unique, flexible, transparent, and proactive approach,” said Dr. Kutzer. “MDP’s extensive experience and strong relationships in the health care and life sciences sectors make them an ideal partner. Looking forward, we will continue to be guided by prioritizing efficient, rapid, and reliable development, while delivering the highest quality and best customer experience in the industry.”

Headquartered within Research Triangle Park (RTP) in Durham, NC, with 10 locations across the globe, Alcami’s services include active pharmaceutical ingredient (API) development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, drug product manufacturing (oral solid dose and parenteral), and packaging and stability services.